Story perspectives

Novo Nordisk Launches Wegovy Subscription Amid Revenue Concerns

4/2/2026

Summary

Story summary

Novo Nordisk A/S launched a Wegovy subscription to boost patient retention amid competition from Eli Lilly and Company, with monthly costs starting at $249 for a 12-month commitment.
The move comes as Novo Nordisk projects a 2026 revenue decline of 5% to 13% due to pricing pressures and competition.
Wegovy received United Kingdom approval for cardiovascular benefits.
Novo Nordisk's shares rose 4.1% after the announcement, remaining significantly below prior highs.

History

Historical Context

In 2021, the FDA approved Wegovy, a weight-loss drug by Novo Nordisk, marking a significant advancement in obesity treatment. This approval coincided with a surge in Denmark's pharmaceutical sector, which saw exports rise from 136.8 million DKK to 157.7 million DKK within a year. The industry's growth has become crucial for Denmark's economy, contributing to two-thirds of its growth in 2022.

1 of 2

Story summary

Novo Nordisk A/S launched a Wegovy subscription to boost patient retention amid competition from Eli Lilly and Company, with monthly costs starting at $249 for a 12-month commitment.
The move comes as Novo Nordisk projects a 2026 revenue decline of 5% to 13% due to pricing pressures and competition.
Wegovy received United Kingdom approval for cardiovascular benefits.
Novo Nordisk's shares rose 4.1% after the announcement, remaining significantly below prior highs.

1 / 2